Jules performs better than Gemini CLI despite using the same model, and more like Claude Code and OpenAI Codex.

Ipsen has reached an agreement to buy fellow French firm ImCheck Therapeutics in a deal that could be worth up to €1 billion ($1.16 billion), adding an antibody-based therapy for acute myeloid ...

Nebius benefits from strong AI infrastructure demand, major hyperscaler contracts, sold-out data centers and ARR growth.